Computer-Aided Drug Design of Falcipain Inhibitors: Virtual Screening, Structure-Activity Relationships, Hydration Site Thermodynamics, and Reactivity Analysis

Falcipains (FPs) are hemoglobinases of Plasmodium falciparum that are validated targets for the development of antimalarial chemotherapy. A combined ligand- and structure-based virtual screening of commercial databases was performed to identify structural analogs of virtual screening hits previously discovered in our laboratory. A total of 28 low micromolar inhibitors of FP-2 and FP-3 were identified and the structure-activity relationship (SAR) in each series was elaborated. The SAR of the compounds was unusually steep in some cases and could not be explained by a traditional analysis of the ligand-protein interactions (van der Waals, electrostatics, and hydrogen bonds). To gain further insights, a statistical thermodynamic analysis of explicit solvent in the ligand binding domains of FP-2 and FP-3 was carried out to understand the roles played by water molecules in binding of these inhibitors. Indeed, the energetics associated with the displacement of water molecules upon ligand binding explained some of the complex trends in the SAR. Furthermore, low potency of a subset of FP-2 inhibitors that could not be understood by the water energetics was explained in the context of poor chemical reactivity of the reactive centers of these compounds. The present study highlights the importance of considering energetic contributors to binding beyond traditional ligand-protein interactions.

[1]  J T Palmer,et al.  Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors , 1996, Antimicrobial agents and chemotherapy.

[2]  P. Rosenthal,et al.  Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Wilson,et al.  Plasmodium falciparum: protease inhibitors and inhibition of erythrocyte invasion. , 1986, Experimental parasitology.

[4]  Ashutosh Kumar Singh,et al.  Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. , 2001, The Biochemical journal.

[5]  Bruce Russell,et al.  Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription , 2011, BMC Genomics.

[6]  Jean-François Truchon,et al.  A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. , 2007, Bioorganic & medicinal chemistry letters.

[7]  Marcin Wiśniewski,et al.  [Achievements and perspectives of research into development of a vaccine against malaria]. , 2010, Wiadomosci parazytologiczne.

[8]  Juan Miguel,et al.  Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. , 2010, Journal of medicinal chemistry.

[9]  William R. Roush,et al.  Structure-Activity Relationships for Inhibition of Cysteine Protease Activity and Development of Plasmodium falciparum by Peptidyl Vinyl Sulfones , 2003, Antimicrobial Agents and Chemotherapy.

[10]  D. Davis,et al.  3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity. , 2003, Bioorganic & medicinal chemistry letters.

[11]  James R Kiefer,et al.  Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. , 2010, Journal of molecular biology.

[12]  B. Berne,et al.  Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. , 2008, Journal of the American Chemical Society.

[13]  Mitchell A. Avery,et al.  Design, Synthesis and Evaluation of Trisubstituted Thiazoles Targeting Plasmodium Falciparum Cysteine Proteases , 2005, Medicinal Chemistry Research.

[14]  Markus Hardt,et al.  Hemoglobin Cleavage Site-Specificity of the Plasmodium falciparum Cysteine Proteases Falcipain-2 and Falcipain-3 , 2009, PloS one.

[15]  Prasenjit Mukherjee,et al.  Computational approaches for the discovery of cysteine protease inhibitors against malaria and SARS. , 2010, Current computer-aided drug design.

[16]  F E Cohen,et al.  Structure-based inhibitor design by using protein models for the development of antiparasitic agents. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[18]  David A. Fidock,et al.  Drug discovery: Priming the antimalarial pipeline , 2010, Nature.

[19]  Jiri Gut,et al.  Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. , 2004, Journal of medicinal chemistry.

[20]  Carlos R Rodrigues,et al.  Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies. , 2002, Journal of medicinal chemistry.

[21]  E. Shaw,et al.  Inhibition of intraerythrocytic development of Plasmodium falciparum by proteinase inhibitors , 1990, FEBS letters.

[22]  P. Rosenthal,et al.  Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease. , 1997, Journal of medicinal chemistry.

[23]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[24]  George M. Whitesides,et al.  Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase , 2011, Proceedings of the National Academy of Sciences.

[25]  Sanjay Batra,et al.  Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-trisubstituted dihydroisoquinolines and isoquinolines. , 2003, Bioorganic & medicinal chemistry.

[26]  Maria Zappalà,et al.  Falcipain‐2 Inhibitors , 2010 .

[27]  P. Rosenthal,et al.  Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. , 1993, The Journal of clinical investigation.

[28]  W. Milhous,et al.  Structure-activity relationships of the antimalarial agent artemisinin. 2. Effect of heteroatom substitution at O-11: synthesis and bioassay of N-alkyl-11-aza-9-desmethylartemisinins. , 1995, Journal of medicinal chemistry.

[29]  Honglin Li,et al.  Identification of novel falcipain-2 inhibitors as potential antimalarial agents through structure-based virtual screening. , 2009, Journal of medicinal chemistry.

[30]  Themis Lazaridis,et al.  Inhomogeneous Fluid Approach to Solvation Thermodynamics. 2. Applications to Simple Fluids , 1998 .

[31]  Tobee Chung,et al.  3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity. , 2003, Bioorganic & medicinal chemistry letters.

[32]  W. Sherman,et al.  Understanding Kinase Selectivity Through Energetic Analysis of Binding Site Waters , 2010, ChemMedChem.

[33]  Jiri Gut,et al.  Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. , 2006, Journal of medicinal chemistry.

[34]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[35]  Jennifer Legac,et al.  Vinyl Sulfones as Antiparasitic Agents and a Structural Basis for Drug Design* , 2009, The Journal of Biological Chemistry.

[36]  P. Rosenthal,et al.  Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. , 1995, Experimental parasitology.

[37]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[38]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[39]  Mitchell A. Avery,et al.  Identification of Novel Malarial Cysteine Protease Inhibitors Using Structure-Based Virtual Screening of a Focused Cysteine Protease Inhibitor Library , 2011, J. Chem. Inf. Model..

[40]  Woody Sherman,et al.  High‐energy water sites determine peptide binding affinity and specificity of PDZ domains , 2009, Protein science : a publication of the Protein Society.

[41]  Prashant Desai,et al.  Homology Modeling of Falcipain-2: Validation, De Novo Ligand Design and Synthesis of Novel Inhibitors , 2002, Journal of biomolecular structure & dynamics.

[42]  P. Rosenthal,et al.  Cysteine proteases of malaria parasites. , 2004, International journal for parasitology.

[43]  Falgun Shah,et al.  Design, synthesis, and development of novel guaianolide-endoperoxides as potential antimalarial agents. , 2010, Journal of medicinal chemistry.

[44]  Woody Sherman,et al.  Contribution of Explicit Solvent Effects to the Binding Affinity of Small‐Molecule Inhibitors in Blood Coagulation Factor Serine Proteases , 2011, ChemMedChem.

[45]  Mitchell A. Avery,et al.  Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors , 2011 .

[46]  P. Rosenthal,et al.  Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. , 1999, Bioorganic & medicinal chemistry.

[47]  Themis Lazaridis,et al.  Thermodynamic contributions of the ordered water molecule in HIV-1 protease. , 2003, Journal of the American Chemical Society.

[48]  W. Milhous,et al.  Structure-activity relationships of the antimalarial agent artemisinin. 1. Synthesis and comparative molecular field analysis of C-9 analogs of artemisinin and 10-deoxoartemisinin. , 1993, Journal of medicinal chemistry.

[49]  Robert Abel,et al.  Motifs for molecular recognition exploiting hydrophobic enclosure in protein–ligand binding , 2007, Proceedings of the National Academy of Sciences.

[50]  C. Higgs,et al.  Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. , 2010, ACS medicinal chemistry letters.

[51]  J T Palmer,et al.  Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. , 1991, The Journal of clinical investigation.

[52]  D. Fidock,et al.  In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. , 2008, International journal for parasitology.

[53]  Fred E. Cohen,et al.  In vitro antimalarial activity of chalcones and their derivatives. , 1995, Journal of medicinal chemistry.

[54]  J. Karle,et al.  Structure-activity relationships of the antimalarial agent artemisinin. 3. Total synthesis of (+)-13-carbaartemisinin and related tetra- and tricyclic structures. , 1996, Journal of medicinal chemistry.

[55]  M. Avery,et al.  Structure-activity relationships of the antimalarial agent artemisinin. 5. Analogs of 10-deoxoartemisinin substituted at C-3 and C-9. , 1996, Journal of medicinal chemistry.

[56]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[57]  M. Ramjee,et al.  Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery. , 2006, The Biochemical journal.

[58]  Linda S. Brinen,et al.  Structures of Falcipain-2 and Falcipain-3 Bound to Small Molecule Inhibitors: Implications for Substrate Specificity‡ , 2009, Journal of medicinal chemistry.

[59]  Gabriele Costantino,et al.  Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: From TIQ-A to HYDAMTIQ , 2011 .

[60]  Y. Ru,et al.  Cyclic ketone inhibitors of the cysteine protease cathepsin K. , 2001, Journal of medicinal chemistry.

[61]  T. Lazaridis Inhomogeneous Fluid Approach to Solvation Thermodynamics. 1. Theory , 1998 .

[62]  Mitchell A. Avery,et al.  Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits , 2008, Bioorganic & Medicinal Chemistry.

[63]  F E Cohen,et al.  In vitro antimalarial activity of chalcones and their derivatives. , 1995, Journal of medicinal chemistry.

[64]  W. Charman,et al.  Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates. , 2002, Journal of medicinal chemistry.